QTTB vs IMVT vs JPM

Q32 Bio Inc.

(QTTB) offers the better valuation at 5. 2x trailing P/E, making it the more compelling value choice. Analysts rate Immunovant, Inc. (IMVT) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Q32 Bio Inc.

(QTTB) is the cheapest at 5. 2x versus JPMorgan Chase & Co. at 15. 6x.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +207. 0%, compared to -90. 2% for Q32 Bio Inc. (QTTB). Over 10 years, the gap is even starker: JPM returned +465. 8% versus QTTB's -96. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Q32 Bio Inc.

(QTTB) is the lower-risk stock at 0. 50β versus Immunovant, Inc. 's 1. 66β — meaning IMVT is approximately 231% more volatile than QTTB relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Q32 Bio Inc.

grew EPS 136. 8% year-over-year, compared to -1. 5% for Immunovant, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Q32 Bio Inc.

(QTTB) is the more profitable company, earning 55. 5% net margin versus 0. 0% for Immunovant, Inc. — meaning it keeps 55. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: QTTB leads at 31. 5% versus 0. 0% for IMVT. At the gross margin level — before operating expenses — QTTB leads at 99. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for IMVT: 32.

8% to $43. 67.

In this comparison, JPM (1.

9% yield) pays a dividend. QTTB, IMVT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Immunovant, Inc. (IMVT) carries a higher beta of 1. 66 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +465. 8%, IMVT: +237. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (QTTB (Healthcare) and IMVT (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: QTTB is a small-cap deep-value stock; IMVT is a small-cap quality compounder stock; JPM is a large-cap deep-value stock. JPM pays a dividend while QTTB, IMVT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.